The reduction of LPS in systemic circulation can inhibit TLR4 in cardiac tissue, reduce the translocation of NF-κB to the nucleus, and release inflammatory cytokines, thereby improving cardiac dysfunction and myocardial fibrosis in DCM. The gene discussed is NFKB1; the disease is familial dilated cardiomyopathy.